John McLean Archives
May. 15, 2018—Four Vanderbilt University faculty members have been named as SEC Academic Leadership Development Program fellows for 2018-19. The program is a professional growth initiative that seeks to identify, prepare and advance academic leaders for roles within SEC institutions and beyond.
Oct. 26, 2017—The Office of Student Leadership Development is hosting the third annual TEDxVanderbiltUniversity event from 1 to 3:30 p.m. Sunday, Nov. 12, in Sarratt Cinema.
Jul. 21, 2015—In the latest VUCast: Find out about a fight club that can save lives; learn how musicians see in tune; and see the best Vanderbilt baseball fans from the College World Series. Watch now.
Jun. 29, 2015—Chemists Brian Bachmann and John McLean have shown that creating bacterial "fight clubs" is an effective way to discover natural biomolecules with the properties required for new drugs.
Mar. 10, 2015—Vanderbilt and the Waters Centers of Innovation Program are sponsoring a free symposium titled "Integrated 'Omics in Translational Medicine" on March 23. It is open to all scientists interested in the subject.
Jun. 20, 2014—Vanderbilt's John McLean has received Agilent Technology's Thought Leader Award in recognition of his contributions to ion mobility mass spectrometry.
Mar. 27, 2014—Vanderbilt physicist John Wikswo reported significant progress toward creating “homo minutus” – a human-on-a-chip that can be used to test drugs and toxins – on Mar. 26 at the Society of Toxicology meeting in Phoenix.
Mar. 3, 2014—Vanderbilt University has been awarded a Cooperative Agreement with the Defense Advanced Research Projects Agency and the Army Research Office that is worth up to $16.5 million over five years.
Jan. 25, 2013—Vanderbilt biochemists have discovered that the process bacteria undergo when they become drug resistant can act as a powerful tool for drug discovery.
Jul. 24, 2012—Creating a device out of human cells that simulates brain chemistry is the goal of a $6.4 million grant which is part of major new federal initiative to develop a series of “organs on a chip” designed to improve the drug development process.